July 11 Two members of the U.S. Senate Finance
Committee, including Chairman Ron Wyden, on Friday asked Gilead
Sciences Inc to defend the more than $80,000 cost of
its breakthrough new treatment for hepatitis C, citing the
expense to federal healthcare programs.
"Given the impact Sovaldi's cost will have on Medicare,
Medicaid and other federal spending, we need a better
understanding of how your company arrived at the price for this
drug," the lawmakers said in a release. "It is unclear how
Gilead set the price for Sovaldi."
The criticism from the two senators follows complaints from
private healthcare insurers about the price of the most potent
new treatment for the dangerous liver disease, which affects
more than 3 million Americans.
Gilead's pill, which cures patients more quickly than older
drugs, and with fewer side effects, captured more than $2
billion in sales during its first full quarter on the market, a
record for the drug industry.
The drugmaker has defended the price, saying Sovaldi
reduces overall treatment costs for hepatitis C by lowering the
number of required healthcare visits and sidestepping the need
for other medicines that treat side effects of older therapies.
Wyden, an Oregon Democrat, and committee member Chuck
Grassley, a Republican from Iowa, said in a letter to Gilead
Chief Executive Officer John Martin that Sovaldi's cost could
also dramatically increase the cost of caring for an estimated
1.8 million prisoners infected with the hepatitis C virus.
(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)